Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma : A lifetime cost-effectiveness analysis.
Analysis of published survival curves has recently been proposed as a method for conducting incremental cost-effectiveness analysis in which two treatments are compared with each other in terms of cost per year of life gained.
In patients with advanced ovarian carcinoma, the combination of paclitaxel and cisplatin has been reported to improve survival more significantly than standard therapy with cyclophosphamide and cisplatin.
However, the high cost of paclitaxel indicates a need for an evaluation of the pharmacoeconomic profile of these treatments.
The authors conducted an incremental cost-effectiveness analysis to assess the paclitaxel-based regimen in terms of cost per year of life gained.
The analysis utilized data from a published controlled long term trial involving 184 patients treated with paclitaxel and cisplatin and 202 patients treated with cyclophosphamide and cisplatin.
Gompertz'law was employed to obtain the lifetime estimate of the years gained by patients given the first treatment in comparison with patients given the second.
The paclitaxel-based treatment was found to improve life expectancy by 46 years for every 100 patients.
Costs of chemotherapy were higher in the paclitaxel group than in the standard-therapy group (the cost difference was $901,723 for every 100 patients ; costs for treating febrile neutropenia induced by chemotherapy were taken into account). (...)
Mots-clés Pascal : Carcinome, Ovaire, Paclitaxel, Cisplatine, Cyclophosphamide, Chimiothérapie, Traitement, Analyse coût efficacité, Economie santé, Etude longitudinale, Etude comparative, Homme, Femelle, Stade avancé, Anticancéreux, Association médicamenteuse, Tumeur maligne, Appareil génital femelle pathologie, Ovaire pathologie, Taxane dérivé, Platine II Complexe, Moutarde à l'azote, Oxazaphosphinane dérivé
Mots-clés Pascal anglais : Carcinoma, Ovary, Paclitaxel, Cisplatin, Cyclophosphamide, Chemotherapy, Treatment, Cost efficiency analysis, Health economy, Follow up study, Comparative study, Human, Female, Advanced stage, Antineoplastic agent, Drug combination, Malignant tumor, Female genital diseases, Ovarian diseases, Taxane derivatives, Platinum II Complexes, Nitrogen mustard, Oxazaphosphinane derivatives
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0030753
Code Inist : 002B02R02. Création : 21/05/1997.